The Society for Immunotherapy of Cancer (SITC) announces the 2022 class of Fellows of the Academy of Immuno-Oncology (FAIO). The luminaries of the 2022 class will be inducted at a private event during SITC's 37th Annual Meeting & Pre-Conference Programs, taking place November 8–12, 2022, in Boston, Massachusetts.
MILWAUKEE, July 14, 2022 /PRNewswire-PRWeb/ -- The Society for Immunotherapy of Cancer (SITC) announces the 2022 class of Fellows of the Academy of Immuno-Oncology (FAIO). The luminaries of the 2022 class will be inducted at a private event during SITC's 37th Annual Meeting & Pre-Conference Programs, taking place November 8–12, 2022, in Boston, Massachusetts.
"I look forward to commemorating the new class of Fellows this fall at the SITC Annual Meeting," said SITC President and Chair of the FAIO Nominating Committee Patrick Hwu, MD. "These individuals are at the vanguard of immuno-oncology and SITC is honored to recognize the impact they have on the field." In addition to the induction ceremony, SITC is hosting a Meet the Fellows (FAIO) event on Thursday, Nov. 10. Annual Meeting participants will have an opportunity to network with both the 2021 and 2022 class of Fellows, learn more about their seminal contributions and celebrate their achievements of the fields of immunotherapy and immuno-oncology.
The 2022 class of the FAIO is:
Rafi Ahmed, PhD – Emory University
Lisa Coussens, PhD, FAACR – Oregon Health & Science University
Mark M. Davis, PhD – Stanford University
Olivera J. Finn, PhD – University of Pittsburgh
Tak Mak, PhD – Princess Margaret Cancer Centre, University Health Network
Cornelis J.M. Melief, MD, PhD – Leiden University & ISA Pharmaceuticals
Lloyd J. Old, MD – Ludwig Institute for Cancer Research – Honored posthumously
Drew M. Pardoll, MD, PhD – Johns Hopkins University
Suzanne L. Topalian, MD – Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy
Giorgio Trinchieri, MD – National Cancer Institute
Louis M. Weiner, MD – Georgetown University/Lombardi Comprehensive Cancer Center
Theresa L. Whiteside, PhD – University of Pittsburgh
SITC solicits nominations and inducts a new class of FAIO on an annual basis. The next call for nominations will be in the spring of 2023.
The Academy of Immuno-Oncology was established by SITC to honor individuals who have helped launch the field of cancer immunotherapy into the breakthrough cancer treatment it is today. It also serves to bring together the brightest minds in the field and advance the SITC mission, the field, and the next generation of immuno-oncologists.
About SITC
Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word "cure" a reality for cancer patients everywhere. Learn more about SITC, our educational offerings and other resources at sitcancer.org and follow us on Twitter, LinkedIn, Facebook and YouTube.
Media Contact
Thomas Martin, Society for Immunotherapy of Cancer, 414-271-2456, [email protected]
SOURCE Society for Immunotherapy of Cancer
Share this article